Use of Allograft Adipose Matrix for Small Joint Arthritis of the Hand
Osteoarthritis Hand
About this trial
This is an interventional treatment trial for Osteoarthritis Hand
Eligibility Criteria
Inclusion Criteria: Patients greater than 18 years, with presentation to the Cedars Sinai hand clinic for joint pain of the hand carpometacarpal, interphalangeal, proximal interphalangeal, and distal interphalangeal joints (CMC, IP, PIP or DIP joints). Radiographic evidence of osteoarthritis. Exclusion Criteria: Prior intervention for the presenting joint (either in the form of cortisone or hyaluronic acid injection or surgery). Rheumatoid or other inflammatory arthritis condition Collagen vascular disease Pregnancy or breast-feeding Congestive heart failure Chronic obstructive pulmonary disease Chronic renal failure Those who had medication or oral supplements for the previous 4 weeks that could prolong bleeding time (e.g.; Aspirin, Plavix).
Sites / Locations
Arms of the Study
Arm 1
Other
Adipose Allograft Matrix (AAM)
Using fluoroscopic guidance (X-ray), a needle will be injected into the joint space. 1 cc of Leneva (adipose allograft matrix, MTF Biologics) will be injected into the joint.